The tiered approach of ESMO in delivering a guidance for cancer patients during the COVID-19 pandemic is designed across three levels of priorities, namely: tier 1 (high priority intervention), 2 (medium priority) and 3 (low priority) – defined according to the criteria of the Cancer Care Ontario, Huntsman Cancer Institute and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS), incorporating the information on the value-based prioritisation and clinical cogency of the interventions
- High priority: Patient's condition is immediately life threatening, clinically unstable, and/or the magnitude of benefit qualifies the intervention as high priority (e.g. significant overall survival [OS] gain and/or substantial improvement in quality of life [QoL]);
- Medium priority: Patient's situation is non-critical but delay beyond 6 weeks could potentially impact overall outcome and/or the magnitude of benefit qualifies for intermediate priority;
- Low priority: Patient's condition is stable enough that services can be delayed for the duration of the COVID-19 pandemic and/or the intervention is non-priority based on the magnitude of benefit (e.g. no survival gain with no change nor reduced QoL).
Download as slides (Powerpoint)
Priorities for ovarian cancer
Documented multidisciplinary tumour team (MDT) decision making, taking into account patient condition (vulnerable patients)* and available resources [Intensive Care Unit (ICU) support for surgery]. If not adequate, refer to or discuss with an Oncological Hub for gynaecological cancers.
Patients and family should be adequately informed about the risk/benefit ratio of each intervention with clinicians taking into account of national therapeutic or interventional guidelines or national specialty recommendations in relation to COVID-19.
*vulnerable patients: >65 years, pre-existing cardiovascular disease, pre-existing respiratory disease
Outpatient visit priorities
High Priority |
---|
|
Medium Priority |
---|
|
Low Priority |
---|
|
For patients on clinical trials, seek information about changes in management for individual studies from the co-ordinating trials unit – treatment frequency; blood investigations and imaging.
Priorities for ovarian cancer: Imaging (CT scan)
High Priority |
---|
|
Medium Priority |
---|
|
Low Priority |
---|
|
Priorities for ovarian cancer: Surgical oncology
High Priority |
---|
|
Medium Priority |
---|
|
Low Priority |
---|
|
Priorities for ovarian cancer: Medical oncology – advanced disease
High Priority |
---|
|
Medium Priority |
---|
|
Low Priority |
---|
|
Priorities for ovarian cancer: Medical oncology – early disease
High Priority |
---|
|
Medium Priority |
---|
|
Low Priority |
---|
|
Chemotherapy in advanced disease:
- Platinum-based therapy, in combination where feasible: carboplatin/paclitaxel every 3-4 weeks (to reduce visits and risk of myelotoxicity). Consider 4-6 cycles depending on response and prognostic factors. Consider reduced number of cycles (4-5) in responding patients before adding PARP inhibitor. Consider early discontinuation of paclitaxel for toxicity
- GCS support to prevent leukopaenia
- Limit dexamethasone to reduce immunosuppression
- Caution with bevacizumab because of the associated hypertension which may worsen COVID-19 outcome, and use of resources with maintenance therapy
- Maintenance with PARP [poly (ADP-ribose) polymerase] inhibitors in high-grade serous/endometriod cancers with a BRCA mutation responding to platinum-based therapy
- In patients who have a BRCA mutation and are PARP naïve, consider rucaparib monotherapy in situations where platinum therapy cannot be given
- Non platinum-based therapies are low priority (above) and should only be used after careful review of the risk/benefit
Chemotherapy in early disease:
- 3-6 cycles carboplatin/paclitaxel (6 cycles in high-grade serous/endometrioid/clear cell)
- Carboplatin 6 cycles
Dose adaptation or single-agent carboplatin (AUC5 every 4 weeks) in vulnerable* patients.
*vulnerable patients: >65 years, pre-existing cardiovascular disease, pre-existing respiratory disease
List of abbreviations: BP, blood pressure; ChT, chemotherapy; CT, computed tomography; NACT, neoadjuvant chemotherapy; PARP, poly (ADP-ribose) polymerase; PARPi, poly (ADP-ribose) polymerase inhibitor; PEG, percutaneous endoscopic gastrostomy; US, ultrasound.
References
Huntsman Cancer Institute Patient Scheduling Recommendations During COVID 19 Crisis 17 March, 2020
NHS Clinical guide for the management of non-coronavirus patients requiring acute treatment: Cancer 23 March 2020, Version 2. https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/03/specialty-guide-acute-treatment-cancer-23-march-2020.pdf (31 March 2020, date last accessed)
BGCS framework for care of patients with gynaecological cancer during the COVID-19 Pandemic (Final. 22/03/2020). https://www.bgcs.org.uk/wp-content/uploads/2020/03/BGCS-covid-guidance-v1.-22.03.2020.pdf (31 March 2020, date last accessed)
SGO surgical considerations for gynecologic oncologists during the COVID-19 pandemic (March 27, 2020). https://www.sgo.org/clinical-practice/management/covid-19-resources-for-health-care-practitioners/surgical-considerations-for-gynecologic-oncologists-during-the-covid-19-pandemic/ (31 March 2020, date last accessed)
Colombo N, Sessa C, du Bois A, et al. ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease. Ann Oncol 2019; 30: 672-705.